

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

ADAPT PHARMA OPERATIONS LIMITED,
ADAPT PHARMA INC., ADAPT PHARMA
LIMITED, and OPIANT
PHARMACEUTICALS, INC.,

Plaintiffs,

v.

PERRIGO UK FINCO LIMITED
PARTNERSHIP,

Defendant.

Consolidated Civil Action No.: 18-CV-
15287

Civil Action No: 18-CV-16987

CONSENT JUDGMENT

Adapt Pharma Operations Limited, Adapt Pharma Inc., Adapt Pharma Limited, and Opiant Pharmaceuticals, Inc. (hereinafter collectively “Adapt”), and Perrigo UK Finco Limited Partnership (hereinafter “Perrigo”), the parties in the above-captioned action, have agreed to terms and conditions representing a negotiated settlement of the action and have set forth those terms and conditions in a Settlement Agreement (the “Settlement Agreement”). Now the parties, by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and an injunction in the action, as follows:

IT IS this 2nd day of March, 2020:

ORDERED, ADJUDGED AND DECREED as follows:

1. This District Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over the parties.
2. As used in this Consent Judgment, (i) the term “Perrigo Product” means the drug product sold, offered for sale or distributed pursuant to Abbreviated New Drug Application No. 211951 (and defined in greater detail in the Settlement Agreement); (ii) the term “Licensed

Patents" means United States Patent Numbers 9,211,253, 9,468,747, 9,561,177, 9,629,965, 9,775,838 and 10,085,937; and (iii) the term "Affiliate" means any entity or person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with Perrigo; for purposes of this definition, "control" means (a) ownership, directly or through one or more intermediaries, of (1) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (2) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity or status as a general partner in any partnership, or (b) any other arrangement whereby an entity or person has the right to elect a majority of the Board of Directors or equivalent governing body of a corporation or other entity or the right to direct the management and policies of a corporation or other entity.

3. Unless otherwise specifically authorized pursuant to the Settlement Agreement, Perrigo, including any of its Affiliates, successors and assigns, is enjoined from infringing the Licensed Patents, on its own part or through any Affiliate, by making, having made, using, selling, offering to sell, importing or distributing of the Perrigo Product.

4. Compliance with this Consent Judgment may be enforced by Adapt and its successors in interest, or assigns, as permitted by the terms of the Settlement Agreement.

5. This District Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and the Settlement Agreement.

6. All claims, counterclaims, affirmative defenses and demands in this action are hereby dismissed with prejudice and without costs, disbursements or attorneys' fees to any party.



Brian R. Martinotti, U.S.D.J.

We hereby consent to the form and entry of this Order:

By: s/ Charles H. Chevalier

Charles H. Chevalier
J. Brugh Lower
GIBBONS P.C.
One Gateway Center
Newark, New Jersey 07102-5310
(973) 596-4500

Attorneys for Plaintiffs
Adapt Pharma Operations Limited,
Adapt Pharma Inc., Adapt Pharma
Limited, and Opiant Pharmaceuticals,
Inc.

OF COUNSEL:

Jessamyn S. Berniker
Ana C. Reyes
David M. Krinsky
David M. Horniak
Jessica Palmer Ryon
Anthony Sheh
Kevin Hoagland-Hanson
Youlin Yuan
WILLIAMS & CONNOLLY LLP
725 Twelfth Street N.W.
Washington, D.C. 20005
(202) 434-5000

Attorneys for Plaintiffs
Adapt Pharma Operations Limited,
Adapt Pharma Inc., and Adapt Pharma
Limited

Robert Green
Jessica Tyrus Mackay
GREEN, GRIFFITH & BORG-BREEN LLP
676 North Michigan Avenue
Suite 3900
Chicago, Illinois 60611
(312) 883-8000

Attorneys for Plaintiff Opiant
Pharmaceuticals, Inc.

By: s/ Geoffrey W. Castello

Geoffrey W. Castello
KELLEY DRYE & WARREN LLP
One Jefferson Road, 2nd Floor
Parsippany, New Jersey 07054
(973) 503-5900
gcastello@kelleydrye.com

OF COUNSEL:

Douglass C. Hochstetler
Constantine Koutsoubas
KELLEY DRYE & WARREN LLP
333 W. Wacker Drive, Suite 2600
Chicago, Illinois 60606
(312) 857-7000

Attorneys for Defendant Perrigo UK
FINCO Limited Partnership